CompoAtlas

Hurix's MoRelief Nasal Inhaler

Hurix's MoRelief Nasal Inhaler : Product registered in Malaysia. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

NPRA, Malaysian pharmaceutical products register, retrieved 27 October 2026.

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
Eucalyptus globulusEucalyptus globulus[169.10 mg,1 ml]Not identified
Mentha piperitaMentha piperita[158.40 mg,1 ml]Not identified
Rosmarinus officinalisRosmarinus officinalis[91.00 mg,1 ml]Not identified
Zingiber officinaleZingiber officinale[87.00 mg,1 ml]Not identified
Foeniculum vulgareFoeniculum vulgare[28.00 mg,1 ml]Not identified
Pogostemon cablinPogostemon cablin[92.00 mg,1 ml]Not identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
MAL20056036TC
Type
Natural product
Published status
PRODUCT APPROVED
Licence holder
JIN BIN CORPORATION SDN. BHD.
Manufacturer
J.B. PHARMACY GROUP SDN. BHD.
Registration period starting
2025-05-07
Published validity end
2030-05-07

Original register data

View published fields and their variants
Active ingredients
Eucalyptus globulus[169.10 mg,1 ml],Mentha piperita[158.40 mg,1 ml],Rosmarinus officinalis[91.00 mg,1 ml],Zingiber officinale[87.00 mg,1 ml],Foeniculum vulgare[28.00 mg,1 ml],Pogostemon cablin[92.00 mg,1 ml]
Valid until
2030-05-07
Registration date
2025-05-07
Published description
NATURAL PRODUCT
Licence holder
JIN BIN CORPORATION SDN. BHD.
Producer
J.B. PHARMACY GROUP SDN. BHD.
Published name
Hurix's MoRelief Nasal Inhaler
Published reference
201906192265T
Registration number
MAL20056036TC
Published status
PRODUCT APPROVED

Official source

View the official register, number MAL20056036TC

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Mentha piperita
    Read the warning, when it applies and the studies cited

    PEPPERMINT - MENTHA X PIPERITA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gallstones or anemia (Brinker 2010; Mills and Bone 2005; Blumenthal et al. 2000).

    Sources cited by Health Canada (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Condition of application: Essential oil.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have hiatus hernia or gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).

    Sources cited by Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Known adverse reactions

    Condition of application: Essential oil.

    When using this product you may experience gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).

    Sources cited by Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Stop use if hypersensitivity/allergy occurs (Mills and Bone 2005; ESCOP 2003).

    Sources cited by Health Canada (2)
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Health Canada monograph dated 27 February 2026

  • Rosmarinus officinalis
    Read the warning, when it applies and the studies cited

    ROSEMARY – ROSMARINUS OFFICINALIS Oral

    Route of administration: Oral (ESCOP 2003)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).

    Sources cited by Health Canada (4)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Health Canada monograph dated 29 May 2026

    ROSEMARY - ROSMARINUS OFFICINALIS Topical

    Route of administration: Topical (ESCOP 2003)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).

    Sources cited by Health Canada (4)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have large open wounds, skin lesions, feverish conditions, acute inflammation, severe circulatory disorders or hypertension (ESCOP 2003).

    Sources cited by Health Canada (1)
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Barnes et al. 2007; ESCOP 2003).

    Sources cited by Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Health Canada monograph dated 29 May 2026

  • Zingiber officinale
    Read the warning, when it applies and the studies cited

    GINGER - ZINGIBER OFFICINALE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 19 December 2025

  • Foeniculum vulgare
    Read the warning, when it applies and the studies cited

    BITTER FENNEL- FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Condition of application: Essential oil and Tincture.

    Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).

    Sources cited by Health Canada (1)
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Health Canada monograph dated 29 November 2024

    SWEET FENNEL -FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Health Canada monograph dated 29 November 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Hurix's MoRelief Nasal Inhaler”, https://compoatlas.com/en/supplements/malaysia/MAL20056036TC-hurix-s-morelief-nasal-inhaler, updated 27 October 2026.

Enter to analyse, Shift+Enter for a new line